Expression of micro-RNA hsa-miR-30c-5p and hsa-miR-138-1 in renal cell carcinoma

Onyshchenko, Kateryna; Voitsitskyi, Taras; Grygorenko, V.; Saidakova, N.O.; Pereta, L.V.; Onyschuk, A P; Skrypkina, Inessa

doi:10.32471/exp-oncology.2312-8852.vol-42-no-2.14632

Cited by 16 publications

(8 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the possible role of miR-30c-5p as a biomarker for early diagnosis or development of recurrence needs further investigation. miR-30c-5p studied here has been shown to be involved in other cancers such as colorectal cancer [32,33], non-small cell lung cancer [34,35], gastric cancer [36], pancreatic ductal adenocarcinoma [37], renal cell carcinoma [38,39], hepatocellular carcinoma [40][41][42][43], breast cancer [44][45][46][47][48], laryngeal cancer [49], and other malignancies. For example, in gastric cancer, miR-30c-5p suppresses migration, invasion, and epithelial to mesenchymal transition via targeting MTA1 [36].…”

Section: Discussionmentioning

confidence: 85%

Salivary miR-30c-5p as Potential Biomarker for Detection of Oral Squamous Cell Carcinoma

Mehterov

Vladimirov

Sacconi³

et al. 2021

Biomedicines

View full text Add to dashboard Cite

The levels of different classes of extracellular RNAs (exRNAs) remain stable in bodily fluids. The detection of either enriched or depleted specific subsets of salivary microRNAs (miRNAs) has the potential to serve as a non-invasive approach for biomarker development. Thus, salivary miRNAs have emerged as a promising molecular tool for early diagnosis and screening of oral squamous cell carcinoma (OSCC). Total RNA was extracted from saliva supernatant of 33 OSCC patients and 12 controls (discovery set), and the differential expression of 8 cancer-related miRNAs was detected by TaqMan assay. Among the screened miRNAs, miR-30c-5p (p < 0.04) was significantly decreased in OSCC saliva. The same transcriptional behavior of miR30c-5p was observed in an additional validation set. miR-30c-5p showed a significant statistical difference between cases and controls with areas under the curve (AUC) of 0.82 (95% CI: 0.71–0.89). The sensitivity and the specificity of miR-30c-5p were 86% and 74%, respectively. The target identification analysis revealed enrichment of miR-30c-5p targets in p53 and Wnt signaling pathways in OSCC. Additionally, the miR-30c-5p targets had clinical significance related to overall survival. In conclusion, these findings show that downregulated miR-30c-5p has the potential to serve as a novel, non-invasive biomarker for early OSCC detection.

show abstract

Section: Discussionmentioning

confidence: 85%

Salivary miR-30c-5p as Potential Biomarker for Detection of Oral Squamous Cell Carcinoma

Mehterov

Vladimirov

Sacconi³

et al. 2021

Biomedicines

View full text Add to dashboard Cite

show abstract

“… 23 In previous studies, the expression of miR-30c-5p was tissue specific, and it exerted both oncogenic and tumor-suppressing roles in different types of cancer. 13 , 14 , 16 , 17 It was reported that aberrant expression of miR-30c was a potential early diagnostic marker in HCC. 18 , 24 Meanwhile, miR-30c downregulation was associated with HCV core protein-induced EMT in HCC cells.…”

Section: Discussionmentioning

confidence: 99%

“… 14 Although miR-30c-5p is considered a potential diagnostic indicator, it has also been reported to act as a tumor promoter in various tumor types. 15 , 16 Inhibiting miR-30c-5p expression offers a possible treatment of isolinderalactone-induced apoptosis for triple-negative breast cancer. 17 A previous study showed that the expression profile of serum miR-30c-5p was found to be deregulated in hepatitis C virus (HCV)-positive HCC.…”

Section: Introductionmentioning

confidence: 99%

Reduced expression of miR-30c-5p promotes hepatocellular carcinoma progression by targeting RAB32

Tian

2021

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) remains among the most lethal of human cancers, despite recent advances in modern medicine. miR-30c-5p is frequently dysregulated in different diseases. However, the effects and the underlying mechanism of miR-30c-5p in HCC are still elusive. Here, we show that miR-30c-5p is downregulated in HCC and significantly associated with survival and tumor size in patients with HCC. We demonstrate that aberrant miR-30c-5p markedly affects HCC cell proliferation and migration. Further experiments show that RAB32 is an essential target of miR-30c-5p in HCC. These studies highlight an important role of miR-30c-5p in growth and invasion of HCC and indicate that the miR-30c-5p-RAB32 axis is an important underlying mechanism.

show abstract

“…MiR-30c-5p is involved in many biological events, including cell apoptosis, growth, and differentiation. In a recent study, decreased expression of miR-30c-5p was associated with an unfavorable course of the renal cell carcinoma [67]. MiR-130a-3p, a member of the miR-130 family, is an important regulator of tumor progression and metastasis [68].…”

Section: Discussionmentioning

confidence: 99%

The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients

Robak

Dróźdż

Jarych³

et al. 2020

Cancers

View full text Add to dashboard Cite

Bortezomib is the first-in-class proteasome inhibitor, commonly used in the treatment of multiple myeloma (MM). The mechanisms underlying acquired bortezomib resistance in MM are poorly understood. Several cell-free miRNAs have been found to be aberrantly regulated in MM patients. The aim of this pilot study was to identify a blood-based miRNA signature that predicts bortezomib-based therapy efficacy in MM patients. Thirty MM patients treated with bortezomib-based regimens were studied, including 19 with refractory disease and 11 who were bortezomib sensitive. Serum miRNA expression patterns were identified with miRCURY LNA miRNA miRNome PCR Panels I+II (Exiqon/Qiagen). Univariate analysis found a total of 21 miRNAs to be differentially expressed in patients with MM according to bortezomib sensitivity. Multivariate logistic regression was created and allowed us to discriminate refractory from sensitive patients with a very high AUC of 0.95 (95%CI: 0.84–1.00); sensitivity, specificity and accuracy were estimated as 0.95, 0.91, and 0.93. The model used expression of 3 miRNAs: miR-215-5p, miR-181a-5p and miR-376c-3p. This study is the first to demonstrate that serum expression of several miRNAs differs between patients who are bortezomib refractory and those who are sensitive which may prove useful in studies aimed at overcoming drug resistance in MM treatment.

show abstract

Expression of micro-RNA hsa-miR-30c-5p and hsa-miR-138-1 in renal cell carcinoma

Cited by 16 publications

References 4 publications

Salivary miR-30c-5p as Potential Biomarker for Detection of Oral Squamous Cell Carcinoma

Salivary miR-30c-5p as Potential Biomarker for Detection of Oral Squamous Cell Carcinoma

Reduced expression of miR-30c-5p promotes hepatocellular carcinoma progression by targeting RAB32

The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients

Contact Info

Product

Resources

About